The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: August 17, 2009

B&W_BigNickelIn addition to the highlights already noted — Enobia’s $50 million r0und, and the LOM – BioQuest joint venture — there was plenty of other Canadian deal activity this week.  Check it out




Clinical Data, Inc. (NASDAQ: CLDA) announced a collaboration and licensing agreement with CombinatoRx (NASDAQ: CRXX).  Clinical Data is licensing its adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential earnings of up to $252 million from milestones and royalties (this In Vivo Blog DoTW post extracts details from the 8-K). CombinatoRx, fresh off the Neuromed transaction, will be responsible for the preclinical and clinical development of ATL313.


Warnex Medical Laboratories, a division of Warnex Inc. (TSX: WNX) and Rosetta Genomics, Ltd. (NASDAQ: ROSG), a developer of microRNA-based molecular diagnostics, announced an exclusive distribution agreement in Canada for three currently-available diagnostic tests for tumor characterization.  Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis.


Bookmark and Share

3 responses to “Monday Deal Review: August 17, 2009

  1. Pingback: Another Biotech Windfall from the SIFT Tax: Vasogen Molts for Cervus and Merges with IntelliPharmaCeutics. Shareholders Applaud. « The Cross-Border Biotech Blog

  2. Pingback: Monday Deal Review: August 28, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Biotech Deal Review: September 14, 2009 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

Join 128 other followers